ArticlePNAS nexus2025
Biophysical basis of tight junction barrier modulation by a pan-claudin-binding molecule.
Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Transforming destructive mechanical cues into therapeutic power: Activation of PIEZO1 and TRPV4 counteracts mechano-induced damage of cellular junctions in Hailey-Hailey disease.Journal of advanced research · 2026Article
- Structure-forward targeting of claudins with synthetic binders.FEBS letters · 2026Review
- Peripheral Myelin Protein-22 and Its Prominence in Charcot-Marie-Tooth Disease.Chemical reviews · 2026Review
- Structures of a synthetic antibody selected against and bound to the C-terminal domain of Clostridium perfringens enterotoxin.Protein science : a publication of the Protein Society · 2025Article
- The epithelial barrier: a Janus-faced regulator in allergic airway diseases from defense to inflammation.Frontiers in allergy · 2025Review
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
Claudins are a 27-member family of membrane proteins that form and fortify specialized cell contacts in endothelium and epithelium called tight junctions. Tight junctions restrict paracellular transport through tissues by forming molecular barriers between cells. Claudin-binding molecules thus hold promise for modulating tight junction permeability to deliver drugs or as therapeutics to treat tight junction-linked disease. The development of claudin-binding molecules, however, is hindered by their physicochemical intractability and small targetable surfaces. Here, we determine that a synthetic antibody fragment (sFab) that we developed binds with nanomolar affinity directly to 10 claudin subtypes and other distantly related claudin family members but not to other tight junction-localized membrane proteins. It does so by targeting the extracellular surfaces of claudins, which we verify by applying this sFab to a model intestinal epithelium and observe that it opens paracellular barriers comparable to a known, but application limited, tight junction modulating protein. This pan-claudin-binding molecule holds potential for both basic and translational applications as it is a probe of claudin and tight junction structure in vitro and in vivo and a tool to modulate the permeability of tight junctions broadly across tissue barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.